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Summal'y 
The expression and function of CD69, a member of the natural killer cell gene complex family 
of signal transducing receptors, was investigated on human monocytes. CD69 was found expressed 
on all peripheral blood monocytes, as a 28- and 32-kD disulfide-linked dimer. Molecular cross- 
linking  of CD69  receptors induced  extracellular  Ca  z §  influx,  as revealed  by flow cytometry. 
CD69 cross-linking resulted also in phospholipase A2 activation, as detected by in vivo arachidonic 
acid release measurement from intact cells and by direct in vitro measurement of enzymatic activity 
using radiolabeled phosphatidylcholine vesicles. Prostaglandin E 2 or, 6-keto-prostaglandin F lc~, 
and leukotriene B4 were detected by radioimmunoassay in supernatants from CD69-stimulated 
monocytes, suggesting  the activation of both cyclooxygenase and lipoxygenase pathways after 
CD69 stimulation.  CD69 cross-linking, moreover, was able to induce strong nitric oxide (NO) 
production from monocytes, as detected by accumulation of NO oxydixed derivatives, and cyclic 
GMP. It is important  to note that NO generation was responsible for CD69-mediated increase 
in spontaneous cytotoxicity against L929 murine transformed fibroblast cell line and induction 
of redirected  cytotoxicity  towards  P815  FctLII +  routine  mastocytoma  cell  line.  These  data 
indicate that CD69 can act as a potent stimulatory molecule on the surface of human peripheral 
blood monocytes. 
C 
D69  is  a  type II  integral  membrane  protein  with  a 
C-type lectin binding domain.  It is a member of the 
natural killer cell gene complex (NKC) family of cell surface 
receptors, as it is the product of a single gene located on syn- 
thetic regions of chromosome  12 in humans  and chromo- 
some 6 in the mouse,  and displays  extended sequence ho- 
mology with the other members of the family (1-4). CD69 
is induced on the surface of recently activated lymphocytes 
(5-9),  likely through  a mechanism  requiring  p21 r~ activa- 
tion (10).  In vivo, CD69 is found constitutively expressed 
on activated lymphoid cells, including CD3  b~ght thymocytes, 
lymph node and tonsil T cells, and gut mucosal T lympho- 
cytes (11-13).  However, CD69 expression is not restricted 
to  activated lymphocytes,  as activated neutrophils  and eo- 
sinophils  can express  CD69  (14,  15).  Moreover,  platelets, 
epidermal  Langerhans  cells,  and  bone  marrow  myeloid 
precursors express CD69 constitutively (16, 17). Such a wide 
distribution suggests a more general role for the CD69 receptor 
in the biology of hematopoietic cells,  as supported also by 
the observation that in all cell types investigated, CD69 cross- 
linking generates an intracellular signal (for a review see ref- 
erence  18), 
We report here on the expression and function of CD69 
on human circulating monocytes. Our data indicate that cir- 
culating monocytes express functional CD69 receptors on their 
cell surface and that the signal generated after CD69 cross- 
linking is a potent activator of monocyte functions, including 
the production of inflammation mediators and the induction 
of cytotoxic activity. 
Materials  and Methods 
Isolation of  Human Monocytes.  Human PBMC were isolated from 
buffy coats  by lymphoprep  gradient  centrifugation  (Nycomed 
Pharma AS, Oslo, Norway) and fractionated on a two-step (43 and 
45.5%) Percoll gradient centrifugation.  Monocytes obtained from 
the Perco11  interface were usually 80-90% pure as assessed  by anti- 
CD14 staining and flow cytometry analysis. Contaminating  T, B, 
and NK cells were eliminated by negative immunomagnetic  selec- 
tion by using  anti-CD2- and anti-CD19-coupled  beads (Dynal, 
Wirral  Merseyside, UK). This procedure routinely  resulted in a 
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staining and  flow cytometry analysis. 
Antibodies,  Immunofluorescence, and  Flow  Cytometry  Analysis. 
Purified anti-CD69 (anti-Leu23, IgG1) and purified anti-CD45RA 
(anti-Leu18,  IgG1) were from Becton Dickinson (San Jose, CA). 
Anti-CD69 F(ab')2 and control mouse F(ab')2 were prepared as pre- 
viously described (16). F(ab')2 goat anti-mouse (GaM) was from 
Organon  Teknika  Corp.  (Durham,  NC).  For  surface  staining, 
PBMC (10Vml) were incubated for 30 min at 4~  with appro- 
priate amounts of the following directly conjugated antibodies (from 
Becton Dickinson): PE anti-CD14 (anti-LeuM3), FITC anti-CD69 
(anti-Leu23),  and isotype-matched FITC and PE control antibodies. 
Samples were analyzed by flow cytometry on a FACScan |  (Becton 
Dickinson). 
Labelin~ Immunoprecipitation, and SDS-PAGE Analysis.  3  x  107 
purified monocytes were washed twice and resuspended in Dul- 
becco's PBS without Ca  2+ and Mg  2+ . ~zsI labeling and lysis in 0.5 
ml 0.5% NP-40 lysis buffer were then performed as previously de- 
scribed (16). Cell lysates were precleared three times with protein 
G-Sepharose (Sigma Chemical Co., St. Louis,  MO) and then in- 
cubated  for 2 h  at  4~  with  anti-CD69  bound  to  protein  G- 
Sepharose.  Immunoprecipitates were run on a 10%  SDS-PAGE. 
Gels were fixed,  dried,  and autoradiographed. 
Ca  2§ Flux Measurements.  Purified monocytes at 107/ml  were 
loaded with 1/~g/ml Pluronic F 127 and 3 #M Fluo-3 (Molecular 
Probes,  Inc., Eugene, OR.) for 45 rain at 37~  in RPMI-1640 with 
1% FCS, which was employed during the whole procedure. Cells 
were then washed and incubated with 10 #g/ml anti-CD69 F(ab')2 
or control mouse F(ab')2.  After two other washes at room tem- 
perature, cells were kept 10 min at 37~  and immediately analyzed 
before and after stimulation with 10 #g/ml F(ab')2 GaM by flow 
cytometry with a FACScan |  as previously described (13). 
Aracbidonic Acid Release.  Monocytes were incubated in serum- 
free medium (RPMI-1640) for 4 h at 37~  with 1 #Ci/ml [5, 6, 
8, 9,  11,  12,  14, 15-3H]-arachidonic  acid (AA) (Amersham, Bucks, 
UK). Labeled  cells were then washed twice, resuspended in fresh 
medium containing 0.01%  fatty acid-free BSA (Sigma Chemical 
Co.) and stimulated with 10 #g/ml F(ab')2 anti-CD69 or control 
mouse F(ab')2 and  10/~g/ml F(ab')2 GaM. AA release  assay was 
carried out in a shaking incubator bath at 37~  and the reaction 
stopped by centrifugation at 14,000 rpm for 1 min. The 3H con- 
tent of the  supernatant  was estimated in a/5 counter. 
Phospholipase A2 Activity Assay.  The cells were treated with 
anti-CD69 mAb (10 #g/ml) or control anti-Leu18  mAb, and GaM 
(10/~g/ml) for 10 min at 37~  and lysed by sonication. Radiola- 
beled phosphatidylcholine (PC) vesicles were prepared by sonicating 
the  radiolabeled phospholipid,  r-a-dipalmitoyl  [choline-methyl- 
14C]PC with a specific activity of 153 mCi/mmol (New England 
Nuclear Inc., Boston, MA).  100 #g of the whole cell lysate was 
added to 250/zl reaction buffer (50 mM Tris HC1, pH 8.5, 5 mM 
C.aC12, 5 mM MgC12, and 0.1% fatty acid-free BSA) containing 
the vesicles at 1/~M, and incubated at 37~  for 1 h. Phospholipids 
were then extracted, applied to a Silica Gel TLC plate (Merck, Darm- 
stadt, Germany), and chromatographed as previously described (19). 
Labeled lyso-PC released  from PC was quantitated and expressed 
as picomoles of lyso-PC per milligrams of protein. 
RIA of Eicosanoids.  The cells were incubated as described above 
in  serum-free medium in  the presence of 10 #g/ml F(ab')2 anti- 
CD69,  or control mouse F(ab')2, in combination with 10 #g/ml 
F(ab')2  GaM.  Commercial  kits  for  eicosanoids  were  purchased 
from New England Nuclear (prostaglandin E 2 a  [PGE2o~] and 
leukotriene B4 [LTB4])  and from Amersham (6-keto-prostaglandin 
F  1 o~ [PGFlo~]). 
Measurement of Nitric Oxide Synthesis.  Nitric oxide (NO) syn- 
thesis was measured as NO2-  accumulation. In aqueous solution, 
NO  reacts  rapidly  with  02  and  accumulates  in  the  culture 
medium  as  NO2-  and  NO3-  ions.  Monocytes were incubated 
with  10 #g/ml F(ab')2 anti-CD69 or control mouse F(ab')2,  to- 
gether with 10 #g/ml F(ab')2 GaM, and 100/~1 of the culture su- 
pernatants were removed for NO2- measurement at the indicated 
times. NO2-  was quantified by a colorimetric assay based on the 
Griess reaction. The OD was measured at 550 nm using a micro- 
ELISA reader (Easy Reader EAR 400;  Kontron Analytic, Milan, 
Italy). 
Cyclic GMP Assay.  Monocytes were incubated with 10 #g/ml 
F(ab')g  anti-CD69  or  control  mouse  F(ab')2,  together  with 
10/~g/ml F(ab')2 GaM. The reaction was stopped at the indicated 
times by addition of ice-cold TCA (10%, wt/vol, final concentra- 
tion). The extraction and the assay were performed as directed in 
the RIA kit  (New England  Nuclear). 
Cytotoxicity Assay.  Assay of monocyte-redirected cytotoxicity 
against murine mastocytoma cell line P815 was performed by in- 
cubating monocytes with 5  x  103 51Cr-labeled (Na2SlCrO4; New 
England Nuclear) tumor cells in triplicate wells,  in the presence 
of 10/~g/ml anti-CD69 or anti-CD45RA mAbs. After 18 h incu- 
bation, supernatant was removed from each well and counted. Assay 
of cytotoxic activity against fibroblast-transformed cell line L929 
was  performed  by  incubating  monocytes  with  5  x  105  3H 
thymidine-labeled (New England Nuclear, Inc.) cells, in the pres- 
ence of 10 #g/ml F(ab')2 anti-CD69 or control mouse F(ab')2, and 
10 #g/ml F(ab')2 GaM. After 18 h incubation, supernatant was re- 
moved from each well and counted. The percentage of specific lysis 
was calculated as follows: 100  x  [(experimental release  -  sponta- 
neous release)/(maximum release -  spontaneous release)]. The NO 
synthase inhibitor, r-MC-monomethyl arginine (t-NMMA; Well- 
come, Beckenham, Kent, UK), was used at 0.5  mM and had no 
effect on target cell viability or spontaneous [3H]thymidine  or 51Cr 
release. 
Results and Discussion 
Monocytes Constitutively Express CD69.  To determine wheth- 
er resting monocytes express CD69,  freshly purified PBMC 
were stained with PE anti-CD14 and FITC anti-CD69 mAb. 
Isotype-matched FITC and PE mouse Ig were used as nega- 
tive controls. Samples were analyzed on a FACScan  |  and data 
were presented in the form of a two-parameter contour plot. 
Fig.  1 A  shows that circulating monocytes,  as identified by 
CD14  expression,  constitutively  express  CD69  molecules. 
SDS-PAGE analysis of anti-CD69 immunoprecipitates from 
purified  monocytes  showed  a  diffuse band  of '~50-60  kD 
under nonreducing conditions,  due to the different dimeric 
combinations, and two bands of 28 and 32 kD under reducing 
conditions  (Fig.  1 B),  indicating  that CD69 on monocytes 
is biochemically similar to that described on lymphocytes and 
platelets  (7,  16). 
CD69  Cross-linking Induces Ca 2+ Influx and Phospholipase 
A2  Activation  in Monocytes.  CD69  cross-linking  has  been 
shown to induce  [Ca  2§ ]i elevation in lymphocytes, platelets, 
and  granulocytes  (14,  16,  20).  To establish whether  CD69 
molecules were able to efficiently transduce a signal in mono- 
cytes, we initially measured intracellular  [Ca 2 +  ]i levels after 
stimulation  with  F(ab')2  anti-CD69,  together  with  GaM 
F(ab')2 to maximize antibody cross-linking.  Fig.  2 A  shows 
2000  Monocyte Activation through  CD69 Figure  1.  (.4)  Two-color  immunofluorescence  anal- 
ysis of human PBL stained with anti-CD14  PE ~v axis) 
and anti-CD69 FITC (x axis). PBL stained with con- 
trol PE and FITC mAbs were contained within the 
lower left quadrant (data not shown). Pour donors  gave 
similar results. (B) SDS-PAGE  analysis of anti-CD69 
immunoprecipitates from human monocytes.  Purified 
monocytes were 12SI-labeled, then material immuno- 
precipitated with anti-CD69-bound protein G-Seph- 
arose (lanes A  and C),  or precleared with  protein 
G-Sepharose (lanes B and D), analyzed  in SDS-PAGE 
under nonreducing  (NR, lanes A and B) and reducing 
(R, lanes C and D) conditions. 
that CD69 triggering in monocytes results in rapid and sus- 
tained [Ca  2+ ]i elevation.  This is most likely due to extracel- 
lular Ca  2+  influx,  since EGTA addition to the medium com- 
pletely  abolished  CD69-induced  intracellular  [Ca2+]i 
elevations. 
CD69 stimulation  on platelets  has been shown to result 
in selective phospholipase A2 (PLA2) activation,  and to be 
sufficient to lead to p|atelet  degranulation  and aggregation 
(19).  To determine whether monocyte CD69 activates PLA2, 
monocytes were labeled  with  3H-AA and  stimulated  with 
anti-CD69  mAbs.  Fig.  2  B  shows  that  3H-AA-labeled 
monocytes released  high  amounts  of radioactive  species  in 
the  medium  after  CD69  stimulation.  To  directly measure 
PLA2 enzymatic activity, cell extracts from CD69-stimulated 
monocytes were incubated with vesicles containing radiola- 
beled PC. After the in vitro reaction, phospholipids were ex- 
tracted  and  chromatographed  on TLC plates,  and lyso-PC 
was detected  and quantitated.  Fig.  2  C  shows that  cell ex- 
tracts from CD69-stimulated  monocytes caused substantial 
release oflyso-PC from PC vesicles, demonstrating that CD69 
is functionally associated to a PLA2 in monocytes. Taken to- 
gether, these data indicate that CD69 receptors may operate 
a very similar signal-transducing apparatus,  which includes 
extracellular  Ca  2  + influx  and PLA2 activation,  in different 
cell  types. 
CD69 Cross-linking  Induces Production of both Cyclooxygenase 
and Lipoxygenase Metabolites.  Most AA produced after PLA2 
activation is oxydized through two main pathways, the lipox- 
ygenase pathway,  producing leukotrienes,  and the cycloox- 
ygenase pathway, giving rise to prostanoids. Both leukotrienes 
and prostanoids are important mediators of inflammation (21). 
We therefore investigated whether AA was undergoing meta- 
bolic oxydation in monocytes after  CD69  triggering.  Fig. 
3 shows that CD69 cross-linking in monocytes induced both 
cyclooxygenase and lipoxygenase products,  as  indicated by 
the release  in the medium  of CD69-stimulated  monocytes 
of  amounts  of  PGE2ot,  6-keto-PGFlot,  and  LTB4  com- 
parable with those generated by LPS stimulation. Considering 
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Figure  2.  Anti-CD69 induced Ca  2+ sig- 
naling  and  PLA2 activation in  human 
monocytes. (.4). Purified monocytes were 
loaded with Fluo-3, labeled with 10 #g/ml 
anti-CD69 F(ab')2 (open triangles) or con- 
trol mouse F(ab')2 (open circles) and ana- 
lyzed by FACS  |  before and after stimula- 
tion at time 0 with 10/xg/ml F(ab')2 GaM. 
2,000 events were recorded  every  20 s. Stim- 
ulation of  CD69-1abeled  cells was also  per- 
formed in the presence of 2.5 mM EGTA 
(closed  triangles). Data from one representa- 
tive donor out of six tested, giving similar 
results, are shown. (B) Monocytes  were la- 
beled with 3H-AA  and stimulated with 10 
/xg/ml anti-CD69 F(ab')2 (open  triangles)  or 
control mouse F(ab')2 (closed  triangles) and 
10/xg/ml F(ab')2 GaM. ~t the times indicated, aliquots from the supernatants were collected and radioactivity measured by 3-scintillation. Data are 
expressed as percent increase in 3H-AA release compared with unstimulated samples. Data from one donor out of two tested, giving similar results, 
are shown. (C) Cell lysates from unstimulated, anti-CD45RA or anti-CD69 stimulated monocytes, were incubated with radiolabeled PC vesicles for 
I h at 37~  Then phospholipids  were extracted and chromatographed, and radiolabeled lyso-PC  was quantified. Results are expressed as percent increase 
in lyso-PC release from PC vesicles compared with unstimulated samples. Data from one donor out of two tested, giving similar results, are shown. 
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Figure  3.  Production  of  PGE2tx,  6-keto-PGFlc~,  and 
LTB4 upon CD69 stimulation. Purified monocytes were in- 
cubated at 106/ml in serum-free medium in the presence of 
10  /~g/ml  anti-CD69  F(ab')2  (shaded columns),  or  mouse 
F(ab')2 control mAb (black columns),  in combination with 
10 #g/ml F(ab')2 GaM. 10/~g/ml LPS (Sigma Chemical Co.) 
was used as positive control (open columns). After 12 h, PGE2ct, 
6-keto-PGFlol,  and LTB4 accumulated in the supernatants 
were measured by P,.IA. Data are expressed as mean  _+  SD 
from five donors tested. 
the wide variety of immunological, vasoactive, and metabolic 
effects exerted by AA metabolites on several different cell types 
in vivo,  cross-linking of monocyte CD69 receptors in vivo 
is  therefore  expected  to  significantly  contribute  to  the 
amplification and regulation of inflammatory processes. 
NO Production by CD69-stimulated  Monocytes.  NO is a reac- 
tive nitrogen intermediate with potent and pleiotropic prop- 
erties, including the capacity to directly kill parasites,  tumor 
cells,  and bacteria  (22-25).  NO  is  extremely unstable  in 
aqueous  solution,  as it  is rapidly oxydized to  NO2-  and 
NO3-.  Moreover, NO stimulates guanylate cyclase activity 
with consequent generation of cyclic guanylate (cGMP). NO 
can be indirectly measured, therefore, by quantitating NO2- 
accumulation and cGMP generation (26). To investigate the 
possibility that stimulation of CD69 in monocytes resulted 
in NO production, we evaluated NO2-  accumulation and 
cGMP generation in anti-CD69-treated monocytes. Fig.  4 
A  shows that, CD69 cross-linking with F(ab')2 anti-CD69 
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Figure 4.  NO  production  from  CD69-stimulated  monocytes.  (A) 
Purified monocytes were stimulated with 10 #g/ml LPS (closed circles), 10 
/~g/ml anti-CD69 F(ab')2 in the absence (closed triangles) or in the pres- 
ence (open triangles) of 0.5 mM r-NMMA, or mouse F(ab')2 control mAb 
(open circles), in combination with 10/~g/ml F(ab')2 GaM. NOz- was re- 
vealed by the Griess reaction, 4,  12, 24, and 48 h after the stimulation. 
Data the expressed  as mean  +  SD from five donors tested.  (B) Purified 
monocytes were stimulated with 10/*g/ml LPS (open triangles), 10/*g/ml 
anti-CD69 F(ab')2 (closed triangles), or mouse F(ab')2 control mAb (open 
circles), in combination with 10 #g/ml F(ab')2 GaM. Cell extracts were 
processed at the indicated time points for cGMP detection by RIA. Data 
are expressed  as mean  _+  SD from four donors tested. 
plus  F(ab')2  GaM,  induced increasing amounts  of NO2- 
over time. In contrast, LPS stimulation, alone or in combi- 
nation with IFN-3' (data not shown), was largely ineffective. 
CD69-dependent  NO2-  accumulation  was  due  to  NO 
generation by NO  synthase,  since NO  synthase inhibitor 
t-NMMA  completely abolished NO2-  accumulation. Ac- 
cordingly moreover, Unlike LPS (or LPS plus IFN-3,, data 
not  shown),  CD69  stimulation  caused  significant cGMP 
generation in monocytes (Fig. 4 B). In contrast to the mu- 
rine system, where the induction of relevant NO production 
from mononuclear phagocytes is induced by two synergistic 
signals,  including IFN-%  IFN-a,  or IFN-/3 plus LPS,  or 
IFN-3, plus TNF-cz or TNF-/5 (27,  28),  human monocytes 
are largely unresponsive to cytokines, even in combination 
with LPS (29).  It is interesting to note that human mono- 
cytes have been shown to produce NO only after interaction 
with tumor cells, but not with untransformed cells, although 
the receptors involved in these interactions remained obscure 
(29). As we observed that cross-linking of monocyte CD69 
receptors induces release of high amounts of NO, this sug- 
gested  that  CD69  cross-linking  could  also  trigger  NO- 
dependent cytotoxicity programs in monocytes. 
CD69 Engagement Induces NO-dependent Cytotoxic Activity 
of Monocytes.  We therefore evaluated whether CD69 cross- 
linking  was  able  to  trigger  monocyte cytotoxic activity 
through a NO-dependent mechanism. We found that anti- 
CD69 stimulation significantly increased spontaneous cyto- 
toxicity against the L929 murine fibroblast line (Fig.  5 A) 
and  induced  redirected  cytotoxicity  towards  the  P815 
FcyRII + murine mastocytoma cell line (Fig.  5 B). It is in- 
teresting that treatment with NO synthase inhibitor t-NMMA 
was able to inhibit both the enhancement of spontaneous cy- 
totoxicity and the induction of redirected cytotoxicity (Fig. 
5 C), indicating that NO generation is directly responsible 
for CD69-induced monocyte cytotoxicity. As mononuclear 
phagocytes play an important role in cancer-related immuno- 
logical processes (30, 31), our data suggest that CD69 cross- 
linking would enable monocytes to exert a potent tumori- 
cidal  activity in vivo,  through the production of reactive 
nitrogen intermediates. 
Concluding Remarks.  Primary sequence analysis and chro- 
mosomal mapping have recently allowed enlistment of CD69 
in  the  NKC  family of signal-transducing  receptors  (32). 
Members of this family, which includes the NKG2 receptors 
in humans, the NKR-P1 receptors in the rat, and the Ly-49 
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Figure  5.  CD69-induced monocyte cy- 
totoxicity. (A) Purified monocytes were in- 
cubated with 3H thymidine-labeled L929 
cells at different E/T ratio for 18 h in the 
presence (closed triangles) or absence (open 
triangles) of 10 #g/ml F(ab')2 anti-CD69, 
or  mouse  F(ab')2 control  mAb  (closed 
circles), in  combination  with  10  #g/ml 
F(ab')2 GaM. 3H release in the  superna- 
tants was measured  by scintillation counting. 
Results are expressed as mean  _+  SD of 
triplicate cultures. Data are from one rep- 
resentative donor out of three tested giving 
similar results. (B) Purified monocytes  were 
incubated with slCr-labeled P815 cells at 
different E/T ratios for 18 h in the pres- 
ence (closed triangles) or absence (open tri- 
angles) of 10/zg/ml anti-CD69, or anti-CD451LA (closed  circles), slCr release in the supernatants was measured by gamma counting. Results are ex- 
pressed as mean  _+ SD of triplicate cultures. Data are from one representative donor out of three tested giving similar results. (C) Monocytes were 
tested as above for cytolytic activity against L929 cells (E/T cell ratio, 3:1) and redirected killing versus P815 cells (E/T cell ratio, 24:1), using control 
mAbs as above described (black columns), anti-CD69 mAbs as above described (st@ed columns) or anti-CD69 mAbs together with 0.5 mM L-NMMA 
(shaded  columns). Results are expressed  as mean + SD of triplicate cultures. Data are from one representative  donor out of three tested giving similar results. 
receptors in the mouse,  are expressed mainly on NK ceils, 
share a remarkable sequence homology, similar topology, and 
molecular assembly. All members of the family, in fact, are 
disulfide-linked homodimers, formed by type II single trans- 
membrane glycoproteins, with a C-type lectin binding do- 
main in the extracellular portion of the molecule. Moreover, 
NKC family members are all able to generate an intracellular 
signal upon molecular cross-linking.  However, a number of 
features clearly distinguish CD69 from other members of the 
family.  NKG2,  NKR-P1,  and Ly-49 receptors,  in  fact,  are 
coded  for by clusters  of crosshybridizing  genes,  some dis- 
playing allelic polymorphism and possible postranscriptional 
regulation by alternative splicing, whereas CD69 is the only 
product of a single nonpolymorphic gene. Moreover, expres- 
sion of most NKC family receptors appears restricted almost 
exclusively to NK cells, in a constitutive fashion. On the con- 
trary,  CD69  is expressed only upon  activation of lympho- 
cytes, including NK cells. Finally, evidence has accumulated 
indicating that CD69 may be expressed on other hematopoi- 
etic cell lineages  (14-17). 
Here we show that CD69 is constitutively expressed on 
human circulating monocytes and  that it is likely to repre- 
sent  an  important  route  to  monocyte  activation,  as cross- 
linking of CD69 receptors is sufficient to induce production 
of key soluble mediators and to trigger NO-dependent cyto- 
toxic  activity  towards  transformed  cell  lines.  Only  the 
identification of natural CD69 ligands,  however, will reveal 
the biological significance of monocyte CD69 expression, and 
the possible relevance in inflammation processes and tumor 
clearance in  vivo. 
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